I really wouldn't put Pfizer in the same group as Apple, Amazon, and the like. What makes those stocks really strong are the lack of scaling costs (meaning they can scale up easily), and strong network effects leading to high barriers of entry (no one can easily compete with them). Pfizer doesn't have any of these advantages, it's recent performance is largely driven by the covid pandemic - which is temporary by nature.